In vitro study of GDNF release from biodegradable PLGA microspheres.

Glial cell line-derived neurotrophic factor (GDNF) is a protein with potent trophic actions on dopaminergic neurons, which is under investigation as a therapeutic agent for the treatment of neurodegenerative disorders, including Parkinson's disease. The aim of this work was to develop GDNF-loaded microspheres, which could be implanted by stereotaxy in the brain and could offer an alternative strategy in the treatment of Parkinson's disease. A w/o/w extraction-evaporation technique was chosen to prepare protein-loaded microspheres. An in vitro release study of the protein was required to assess the retention of integrity and the performance of the microsphere formulation with regard to sustained release. In order to assess the in vitro release profile of the GDNF-loaded microspheres, a preliminary study was performed to select an appropriate buffer for GDNF stabilization, using experimental designs. GDNF was measured by both enzyme-linked immunosorbant assay (ELISA) and radioactivity using (125)I-GDNF. The GDNF-loaded microsphere release profile was assessed in a low continuous flow system, and showed a sustained release over 56 days of biologically active GDNF at clinically relevant doses.

[1]  D. Volkin,et al.  The adsorption of proteins to pharmaceutical container surfaces , 1992 .

[2]  J. Benoit,et al.  A Novel in Vitro Delivery System for Assessing the Biological Integrity of Protein upon Release from PLGA Microspheres , 2002, Pharmaceutical Research.

[3]  J. Benoit,et al.  Why Does PEG 400 Co-Encapsulation Improve NGF Stability and Release from PLGA Biodegradable Microspheres? , 1999, Pharmaceutical Research.

[4]  Michael Sendtner,et al.  Microencapsulated Ciliary Neurotrophic Factor: Physical Properties and Biological Activities , 1996, Experimental Neurology.

[5]  Charles F. Morris,et al.  Aggregation Pathway of Recombinant Human Keratinocyte Growth Factor and Its Stabilization , 1994, Pharmaceutical Research.

[6]  Richard Grondin,et al.  Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys. , 2002, Brain : a journal of neurology.

[7]  R. Almon,et al.  ASSOCIATIONS OF BETA NERVE GROWTH FACTOR WITH BOVINE SERUM ALBUMIN AS WELL AS WITH THE ALPHA AND GAMMA SUBUNITS OF THE 7S MACROMOLECULE 1 , 1978, Journal of neurochemistry.

[8]  I. Date,et al.  The effect of intrastriatal single injection of GDNF on the nigrostriatal dopaminergic system in hemiparkinsonian rats: behavioral and histological studies using two different dosages , 2000, Neuroscience Research.

[9]  L. Olson,et al.  Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  K. Çiftçi,et al.  Formulation of Proteins and Peptides , 2005 .

[11]  A. Klibanov,et al.  Stability of Proteins and Their Delivery from Biodegradable Polymer Microspheres , 1996 .

[12]  C. Svendsen,et al.  Neurospheres modified to produce glial cell line‐derived neurotrophic factor increase the survival of transplanted dopamine neurons , 2002, Journal of neuroscience research.

[13]  L. Olson,et al.  Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo , 1995, Nature.

[14]  A. Granholm,et al.  A non‐invasive transport system for GDNF across the blood–brain barrier , 1997, Neuroreport.

[15]  I. Strömberg,et al.  Implantation of Bioactive Growth Factor-Secreting Rods Enhances Fetal Dopaminergic Graft Survival, Outgrowth Density, and Functional Recovery in a Rat Model of Parkinson's Disease , 2000, Experimental Neurology.

[16]  B. Hoffer,et al.  Functional recovery in parkinsonian monkeys treated with GDNF , 1996, Nature.

[17]  N. Déglon,et al.  Comparative study of GDNF delivery systems for the CNS: polymer rods, encapsulated cells, and lentiviral vectors. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[18]  D. Brooks,et al.  Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease , 2003, Nature Medicine.

[19]  Tracy Chen,et al.  Formulation concerns of protein drugs , 1992 .

[20]  W Wang,et al.  Instability, stabilization, and formulation of liquid protein pharmaceuticals. , 1999, International journal of pharmaceutics.

[21]  T. Hagg,et al.  Glial cell line‐derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats , 1997, The Journal of comparative neurology.

[22]  A. Björklund,et al.  Sequential Administration of GDNF into the Substantia Nigra and Striatum Promotes Dopamine Neuron Survival and Axonal Sprouting but Not Striatal Reinnervation or Functional Recovery in the Partial 6-OHDA Lesion Model , 2000, Experimental Neurology.

[23]  J. Benoit,et al.  Striatal implantation of GDNF releasing biodegradable microspheres promotes recovery of motor function in a partial model of Parkinson's disease. , 2004, Biomaterials.

[24]  C. Spenger,et al.  Implants of Polymer-Encapsulated Genetically Modified Cells Releasing Glial Cell Line-Derived Neurotrophic Factor Improve Survival, Growth, and Function of Fetal Dopaminergic Grafts , 1998, Experimental Neurology.

[25]  Jean-Pierre Benoit,et al.  Bovine serum albumin release from poly(α-hydroxy acid) microspheres: effects of polymer molecular weight and surface properties , 1997 .

[26]  B. J. Baumgartner,et al.  Neuroprotection of Spinal Motoneurons Following Targeted Transduction with an Adenoviral Vector Carrying the Gene for Glial Cell Line-Derived Neurotrophic Factor , 1998, Experimental Neurology.

[27]  Smadar Cohen,et al.  Microparticulate Systems for the Delivery of Proteins and Vaccines , 2020 .

[28]  G. Gerhardt,et al.  GDNF improves dopamine function in the substantia nigra but not the putamen of unilateral MPTP-lesioned rhesus monkeys , 1999, Brain Research.

[29]  Timothy Sendera,et al.  Clinicopathological findings following intraventricular glial‐derived neurotrophic factor treatment in a patient with Parkinson's disease , 1999, Annals of neurology.

[30]  I. Fariñas,et al.  Renal and neuronal abnormalities in mice lacking GDNF , 1996, Nature.

[31]  C. Henderson,et al.  GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. , 1994, Science.

[32]  F. Collins,et al.  Purification and Initial Characterization of Rat B49 Glial Cell Line‐Derived Neurotrophic Factor , 1994, Journal of neurochemistry.

[33]  S. Schwendeman,et al.  Stabilization of Proteins Encapsulated in Cylindrical Poly(lactide-co-glycolide) Implants: Mechanism of Stabilization by Basic Additives , 2000, Pharmaceutical Research.

[34]  D. Hilt,et al.  Pharmacological Activities of Glial Cell Line-Derived Neurotrophic Factor (GDNF): Preclinical Development and Application to the Treatment of Parkinson's Disease , 1997, Experimental Neurology.

[35]  Kinam Park,et al.  Controlled drug delivery : challenges and strategies , 1997 .

[36]  J. Benoit,et al.  Development of microspheres for neurological disorders: from basics to clinical applications. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[37]  J. Benoit,et al.  NGF release from poly(D,L-lactide-co-glycolide) microspheres. Effect of some formulation parameters on encapsulated NGF stability. , 1998, Journal of controlled release : official journal of the Controlled Release Society.

[38]  L. Olson,et al.  The effect of glial cell line-derived neurotrophic factor in fibrin glue on developing dopamine neurons , 2004, Experimental Brain Research.

[39]  H. Sah.  Stabilization of proteins against methylene chloride/water interface-induced denaturation and aggregation. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[40]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.

[41]  J. Bloch,et al.  Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. , 2000, Science.

[42]  E. Arenas,et al.  GDNF prevents degeneration and promotes the phenotype of brain noradrenergic neurons in vivo , 1995, Neuron.

[43]  D. Guilloteau,et al.  Protection of dopaminergic nigrostriatal afferents by GDNF delivered by microspheres in a rodent model of Parkinson's disease , 2002, Synapse.

[44]  J. Lile,et al.  GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. , 1993, Science.

[45]  J. Benoit,et al.  Biodegradation and brain tissue reaction to poly(D,L-lactide-co-glycolide) microspheres. , 1993, Biomaterials.

[46]  D. Yurek.  Glial Cell Line-Derived Neurotrophic Factor Improves Survival of Dopaminergic Neurons in Transplants of Fetal Ventral Mesencephalic Tissue , 1998, Experimental Neurology.

[47]  D. Maysinger,et al.  In vitro effects of brain derived neurotrophic factor released from microspheres. , 1994, Neuroreport.

[48]  M. Saarma,et al.  Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. , 2000, Science.